TN-ARIES-CLEAN-TECH
19.11.2021 17:49:06 CET | Business Wire | Press release
Aries has reached another major milestone, achieving mechanical completion of the Aries Linden Biosolids Gasification Plant in Linden, New Jersey. This fluidized bed gasification plant is currently the largest facility of its type in the world. Commissioning is underway and is expected to be completed over the next few months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211119005608/en/
At full capacity, the plant will process 430 tons of biosolids daily (130,000 tons per year) diverting it from local landfills. This will also result in the production of approximately 22 tons per day of beneficial Bio-Fly-Ash™, a renewable product that will be sold as an additive to local concrete companies. The plant is located in a re-purposed building within the Linden Roselle Sewerage Authority (LRSA) complex.
“A special congratulations to Renus Kelfkens, Aries Executive Vice President - Engineering and all the Aries Clean Technologies team on this major milestone,” said Gregory Bafalis , CEO of Aries. “These teams have worked thousands of hours and delivered all fabrication and installation within two years from groundbreaking. I have no doubt this technology will become a new standard for the safe conversion of biosolids into beneficial use products.
“Currently 90% of the domestic Class A biosolids market is disposed of through ineffective conventional means such as landfilling, land application, or incineration. The fluidized bed technology can safely and efficiently stop this now and generate clean energy and Bio-Fly-Ash™,” Bafalis added.
“We’ve looked forward to celebrating this historic date that brings new technology and progress towards a cleaner environment to Linden and the Garden State,” said Derek Armstead , Mayor of Linden. “The Aries Build-Own-Operate model provides no financial risk to the LRSA or to the City of Linden but brings with it new, high-paying, green jobs in the clean tech industry for the people of Linden. And I’m so pleased that 16 new, permanent positions will bring this plant to life. We look forward to a long partnership with the Aries Linden team.”
Even before construction began, collaborations were underway with LRSA and the State of New Jersey Department of Environmental Protection (NJDEP). The awarding of the environmental permits not only validates Aries biosolids solutions but helps bring the state closer to its environmental goals. Permits addressed areas such as site use, soil conservation, air quality, water usage, and electrical generation and consumption.
Financing was provided in part through the sale of $61.5 million of “Green” tax-exempt bonds issued through the Union County Improvement Authority. Equity for the project comes principally from Aries Clean Technologies and Spring Lane Capital . “This project and Aries’ gasification technology fit perfectly with Spring Lane’s investment approach of partnering with leaders in the energy, water, food, and waste industries to help them deploy innovative, sustainable solutions. We are thrilled to support the Aries team on this and future projects,” said Nikhil Garg, General Partner at Spring Lane Capital.
Current research indicates that the fluidized bed gasification process will become an efficient method to address and destroy the quickly growing problem of per- and polyfluoroalkyl substances (PFAS). These man-made chemicals are used in many industrial applications and are very pervasive in the environment and human body. PFAS accumulates over time, leading to adverse health effects. Current studies show that the high temperature reached during the gasification process destroys any PFAS in biosolids as well as other bacteria, viruses, mold, fungus, etc.
The closed-loop system runs primarily on clean sustainable, renewable synthetic gas rather than relying on fossil fuels during operations. It is carbon negative and captures methane (with a global warming impact 23 times greater than CO2) that would otherwise be released into the atmosphere through the decomposition of biosolids. Greenhouse gases will also be reduced due to the reduction in trucking miles to reach existing, conventional disposal methods.
LRSA, created in 1948, services the City of Linden and the Borough of Roselle. It was established to contract and operate wastewater treatment and interceptor facilities to collect, treat, and dispose of sewage generated by the municipalities.
In addition to being the lowest cost option for biosolids disposal in the Linden area, the plant will serve the largest metropolitan area in the U.S., New York, that includes New York City, Long Island, and the Mid and Lower Hudson Valley in the state of New York and five of the largest cities in New Jersey: Newark, Jersey City, Paterson, Elizabeth, and Edison, and their vicinities.
About Aries Clean Technologies
Aries Clean Technologies, based in Franklin, Tennessee, develops, designs, and builds innovative proprietary fluidized bed and downdraft gasification systems and projects using its eight patents granted to date. Its projects provide for the sustainable conversion of biosolids and biomass, reduction of carbon emissions, and the production of clean thermal and electrical energy and beneficial Aries GREEN ® Biochar or Bio-Fly-Ash™. For more information, please visit our website: www.ariescleantech.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005608/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
